NeuroMetrix (NASDAQ:NURO) Issues Quarterly Earnings Results

NeuroMetrix (NASDAQ:NURO) posted its quarterly earnings data on Tuesday. The medical device company reported ($0.75) earnings per share (EPS) for the quarter, RTT News reports. The company had revenue of $0.59 million for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%. During the same quarter last year, the firm posted ($1.66) earnings per share.

NeuroMetrix Price Performance

NASDAQ:NURO opened at $3.84 on Friday. The firm has a market capitalization of $7.78 million, a price-to-earnings ratio of -0.84 and a beta of 2.29. The company’s 50-day moving average is $4.03 and its two-hundred day moving average is $3.88. NeuroMetrix has a 1-year low of $2.66 and a 1-year high of $4.73.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of NeuroMetrix in a research report on Monday. They set a “sell” rating on the stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.